The overall survival impact of prophylactic cranial irradiation in limited-stage small-cell lung cancer: A systematic review and meta-analysis.
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
28
01
2022
revised:
06
02
2022
accepted:
10
02
2022
entrez:
4
3
2022
pubmed:
5
3
2022
medline:
5
3
2022
Statut:
epublish
Résumé
Prophylactic cranial irradiation (PCI) for limited-stage small-cell lung cancer (LS-SCLC) patients has become more controversial. Since the publication of the systematic review by Aupérin et al. in 1999, no randomized controlled trials regarding PCI in LS-SCLC have been completed. The aim of this study was to systematically review and meta-analyze the effect of PCI on overall survival (OS) in patients with LS-SCLC. A systematic search was conducted in the databases of MEDLINE (PubMed), Embase and the Cochrane library. Only studies that reported an adjusted hazard ratio (aHR), indicating the effect of PCI versus no PCI on OS (adjusted for confounders) in patients with LS-SCLC were included for critical appraisal and meta-analysis. A pooled aHR estimate was calculated using a random-effects model. Pooling of 28 retrospective studies including a total of 18,575 patients demonstrated a significant beneficial effect of PCI versus no PCI on OS with a pooled aHR of 0.62 (95% CI: 0.57-0.69). Substantial heterogeneity of reported aHRs among studies was observed (I This meta-analysis demonstrates a significant beneficial effect of PCI on OS in patients with LS-SCLC. Larger studies reported a milder beneficial effect, possibly due to a decreased risk of model overfitting. Serious risk of selection and confounding bias were of concern due to the lack of prospective trials. These results support the role of PCI in standard clinical practice in patients with LS-SCLC while awaiting results of prospective trials on alternative strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Prophylactic cranial irradiation (PCI) for limited-stage small-cell lung cancer (LS-SCLC) patients has become more controversial. Since the publication of the systematic review by Aupérin et al. in 1999, no randomized controlled trials regarding PCI in LS-SCLC have been completed. The aim of this study was to systematically review and meta-analyze the effect of PCI on overall survival (OS) in patients with LS-SCLC.
METHODS
METHODS
A systematic search was conducted in the databases of MEDLINE (PubMed), Embase and the Cochrane library. Only studies that reported an adjusted hazard ratio (aHR), indicating the effect of PCI versus no PCI on OS (adjusted for confounders) in patients with LS-SCLC were included for critical appraisal and meta-analysis. A pooled aHR estimate was calculated using a random-effects model.
RESULTS
RESULTS
Pooling of 28 retrospective studies including a total of 18,575 patients demonstrated a significant beneficial effect of PCI versus no PCI on OS with a pooled aHR of 0.62 (95% CI: 0.57-0.69). Substantial heterogeneity of reported aHRs among studies was observed (I
CONCLUSIONS
CONCLUSIONS
This meta-analysis demonstrates a significant beneficial effect of PCI on OS in patients with LS-SCLC. Larger studies reported a milder beneficial effect, possibly due to a decreased risk of model overfitting. Serious risk of selection and confounding bias were of concern due to the lack of prospective trials. These results support the role of PCI in standard clinical practice in patients with LS-SCLC while awaiting results of prospective trials on alternative strategies.
Identifiants
pubmed: 35243025
doi: 10.1016/j.ctro.2022.02.002
pii: S2405-6308(22)00005-2
pmc: PMC8881197
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
145-152Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Clin Oncol. 2021 Oct 1;39(28):3118-3127
pubmed: 34379442
J Clin Oncol. 2016 Apr 1;34(10):1057-64
pubmed: 26786925
Thorac Cancer. 2020 May;11(5):1239-1244
pubmed: 32142599
Clin Oncol (R Coll Radiol). 2021 Aug;33(8):e323-e330
pubmed: 33888381
Clin Transl Radiat Oncol. 2021 Feb 12;27:157-163
pubmed: 33665386
JAMA Netw Open. 2019 Aug 2;2(8):e199135
pubmed: 31411707
J Clin Oncol. 2009 Jan 1;27(1):78-84
pubmed: 19047288
Lancet Oncol. 2017 May;18(5):663-671
pubmed: 28343976
J Thorac Dis. 2019 Mar;11(3):811-818
pubmed: 31019769
J Radiat Res. 2019 Oct 23;60(5):630-638
pubmed: 31165148
Pract Radiat Oncol. 2019 Nov;9(6):e599-e607
pubmed: 31271904
J Cancer. 2018 Sep 8;9(19):3500-3506
pubmed: 30310506
Ann Oncol. 2021 Jul;32(7):839-853
pubmed: 33864941
Cancer. 2009 Feb 15;115(4):842-50
pubmed: 19117355
N Engl J Med. 1999 Aug 12;341(7):476-84
pubmed: 10441603
Cancer. 2013 Nov 1;119(21):3753-60
pubmed: 23921891
Acta Oncol. 2022 Feb;61(2):185-192
pubmed: 34583620
J Thorac Oncol. 2017 Feb;12(2):347-353
pubmed: 27725211
Clin Lung Cancer. 2017 Jul;18(4):e243-e249
pubmed: 28065620
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
JAMA Netw Open. 2020 Apr 1;3(4):e201929
pubmed: 32236532
N Engl J Med. 2020 Aug 13;383(7):640-649
pubmed: 32786189
Radiat Oncol. 2017 Mar 11;12(1):51
pubmed: 28283034
Radiother Oncol. 2017 Feb;122(2):307-312
pubmed: 28073578
Cancer Treat Rep. 1983 Jul-Aug;67(7-8):675-82
pubmed: 6307516
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Thorac Oncol. 2018 Apr;13(4):497-509
pubmed: 29360512
Lung Cancer. 2014 Dec;86(3):334-8
pubmed: 25453847
Radiother Oncol. 2017 Oct;125(1):130-135
pubmed: 28778345
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Cancer. 2010 Dec 15;116(24):5694-9
pubmed: 20803612
J Thorac Oncol. 2007 Jun;2(6):506-13
pubmed: 17545845
Oncotarget. 2018 Apr 3;9(25):17664-17674
pubmed: 29707139
Oncol Lett. 2020 Jan;19(1):239-246
pubmed: 31897135
Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):77-84
pubmed: 20800380
J Thorac Cardiovasc Surg. 2021 Mar;161(3):760-771.e2
pubmed: 33349449
J Radiat Res. 2018 Nov 1;59(6):767-773
pubmed: 30102326
Am J Clin Oncol. 2020 Apr;43(4):236-242
pubmed: 31842113
J Natl Cancer Inst. 1995 Feb 1;87(3):183-90
pubmed: 7707405
Lung Cancer. 1998 Sep;21(3):193-201
pubmed: 9857997
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Clin Transl Radiat Oncol. 2021 Jul 08;30:43-49
pubmed: 34296000
J Med Imaging Radiat Oncol. 2021 Oct;65(6):778-785
pubmed: 34159731
Future Oncol. 2019 Jan;15(1):3237-3245
pubmed: 30091368
Oncology (Williston Park). 1998 Jan;12(1 Suppl 2):19-24
pubmed: 9516607
J Thorac Oncol. 2021 May;16(5):840-849
pubmed: 33545387
Lung Cancer. 1993 Oct;10(1-2):47-54
pubmed: 8069603
Cancer Manag Res. 2019 Oct 23;11:9049-9055
pubmed: 31749631
J Med Imaging Radiat Oncol. 2013 Feb;57(1):105-12
pubmed: 23374562